MX2023007496A - Antifolatos poliglutamados y sus usos. - Google Patents
Antifolatos poliglutamados y sus usos.Info
- Publication number
- MX2023007496A MX2023007496A MX2023007496A MX2023007496A MX2023007496A MX 2023007496 A MX2023007496 A MX 2023007496A MX 2023007496 A MX2023007496 A MX 2023007496A MX 2023007496 A MX2023007496 A MX 2023007496A MX 2023007496 A MX2023007496 A MX 2023007496A
- Authority
- MX
- Mexico
- Prior art keywords
- polyglutamated antifolates
- polyglutamated
- antifolates
- formulations
- disorders
- Prior art date
Links
- 230000003432 anti-folate effect Effects 0.000 title abstract 5
- 229940127074 antifolate Drugs 0.000 title abstract 5
- 239000004052 folic acid antagonist Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 abstract 3
- 239000002502 liposome Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Abstract
La descripción hace referencia, en términos generales, a antifolatos poliglutamados, formulaciones que contienen liposomas rellenos con los antifolatos poliglutamados, métodos para realizar las formulaciones que contienen liposomas y los antifolatos poliglutamados, así como métodos para utilizar las formulaciones que contienen liposomas y antifolatos poliglutamados para tratar trastornos hiperproliferativos (por ejemplo, cáncer) y trastornos del sistema inmunológico (por ejemplo, una enfermedad autoinmune, como artritis reumatoide).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662374458P | 2016-08-12 | 2016-08-12 | |
US201715675695A | 2017-08-11 | 2017-08-11 | |
US15/675,701 US20180236098A1 (en) | 2016-08-12 | 2017-08-11 | Alpha and gamma-d polyglutamated antifolates and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023007496A true MX2023007496A (es) | 2023-07-05 |
Family
ID=65235618
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019001756A MX2019001756A (es) | 2016-08-12 | 2017-08-12 | Antifolatos poliglutamados alfa y gamma-d y sus usos. |
MX2019001755A MX2019001755A (es) | 2016-08-12 | 2017-08-12 | Antifolatos poliglutamados y sus usos. |
MX2022009187A MX2022009187A (es) | 2016-08-12 | 2019-02-11 | Antifolatos poliglutamados alfa y gamma-d y sus usos. |
MX2023007496A MX2023007496A (es) | 2016-08-12 | 2019-02-11 | Antifolatos poliglutamados y sus usos. |
MX2023007726A MX2023007726A (es) | 2016-08-12 | 2019-02-11 | Antifolatos poliglutamados alfa y gamma-d y sus usos. |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019001756A MX2019001756A (es) | 2016-08-12 | 2017-08-12 | Antifolatos poliglutamados alfa y gamma-d y sus usos. |
MX2019001755A MX2019001755A (es) | 2016-08-12 | 2017-08-12 | Antifolatos poliglutamados y sus usos. |
MX2022009187A MX2022009187A (es) | 2016-08-12 | 2019-02-11 | Antifolatos poliglutamados alfa y gamma-d y sus usos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023007726A MX2023007726A (es) | 2016-08-12 | 2019-02-11 | Antifolatos poliglutamados alfa y gamma-d y sus usos. |
Country Status (10)
Country | Link |
---|---|
US (6) | US11344628B2 (es) |
EP (3) | EP4052729A1 (es) |
JP (4) | JP2019524885A (es) |
KR (4) | KR102584446B1 (es) |
CN (2) | CN109689104A (es) |
AU (4) | AU2017308158B2 (es) |
BR (2) | BR112019002497A2 (es) |
CA (3) | CA3033083A1 (es) |
EA (1) | EA201990473A1 (es) |
MX (5) | MX2019001756A (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019001756A (es) | 2016-08-12 | 2019-05-09 | L E A F Holdings Group Llc | Antifolatos poliglutamados alfa y gamma-d y sus usos. |
WO2019157146A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
US20210161899A1 (en) * | 2018-02-07 | 2021-06-03 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
JP7490240B2 (ja) * | 2018-02-07 | 2024-05-27 | エル.イー.エー.エフ. ホールディングス グループ エルエルシー | ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用 |
EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | PRALATREXATE ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
US20210338675A1 (en) * | 2018-02-07 | 2021-11-04 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
WO2019157138A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pemetrexed and uses thereof |
WO2019157123A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
JP7491573B2 (ja) * | 2018-02-07 | 2024-05-28 | エル.イー.エー.エフ. ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
WO2019160733A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
CA3090875A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
WO2019160736A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
WO2021026310A1 (en) * | 2019-08-06 | 2021-02-11 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
CN112010862B (zh) * | 2020-10-23 | 2021-03-30 | 南京诺源医疗器械有限公司 | 一种主动靶向叶酸受体近红外荧光分子及其制备方法 |
WO2023180103A1 (en) * | 2022-03-21 | 2023-09-28 | Immundiagnostik Ag | Kit of parts and microbiological method for assessment of the folate status in serum and red blood cells |
JP2024060824A (ja) * | 2022-10-20 | 2024-05-07 | プレミアアンチエイジング株式会社 | 経口製剤及びその製造方法 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4584375A (en) * | 1984-08-21 | 1986-04-22 | Rensselaer Polytechnic Institute | Fluorine-containing antifolates incapable of polyglutamate formation |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0492316A1 (en) | 1990-12-14 | 1992-07-01 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic oligoglutamate derivatives, their production and pharmaceutical compositions containing them |
US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
CN1122456C (zh) | 1996-01-31 | 2003-10-01 | 南亚拉巴马医学科学基金会 | 含有天然的还原叶酸盐异构体的食品和维生素制品 |
US5912251A (en) | 1998-01-17 | 1999-06-15 | Nair; Madhavan G. | Metabolically inert anti-inflammatory and anti-tumor antifolates |
US20050031679A1 (en) | 1998-03-27 | 2005-02-10 | Clemens Unger | Method for producing liposomal formulations of active ingredients |
EP1095077B1 (en) | 1998-07-09 | 2005-04-06 | Rhodia Chimie | Water-soluble or water-dispersible grafted copolymers |
WO2001005405A1 (en) | 1999-07-16 | 2001-01-25 | The General Hospital Corporation | Folylpolyglutamyl synthetase gene transfer to enhance antifolate drug sensitivity |
WO2001053331A2 (en) | 2000-01-24 | 2001-07-26 | Adherex Technologies, Inc. | Peptidomimetic modulators of cell adhesion |
CN1095472C (zh) | 2000-04-17 | 2002-12-04 | 上海复康医药科技发展有限公司 | 叶酸-多聚糖复合物,其制备方法和以该复合物为活性成分的药物组合物 |
US6689381B2 (en) | 2000-06-09 | 2004-02-10 | Osi Pharmaceuticals, Inc. | Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
DE60127970T2 (de) | 2000-06-30 | 2007-12-20 | Eli Lilly And Co., Indianapolis | Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält |
CH696628A5 (de) | 2002-02-26 | 2007-08-31 | Eprova Ag | Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der |
US7563590B2 (en) | 2002-08-30 | 2009-07-21 | Cypress Bioscience Inc. | Methods of quantifying methotrexate metabolites |
US6921667B2 (en) * | 2003-03-07 | 2005-07-26 | Prometheus Laboratories, Inc. | Methods for direct detection of individual methotrexate metabolites |
NZ589967A (en) | 2004-01-14 | 2012-07-27 | Gilead Sciences Inc | Lipid-based dispersions useful for drug delivery |
WO2005080431A2 (en) | 2004-02-12 | 2005-09-01 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
US7612071B2 (en) | 2004-03-12 | 2009-11-03 | Syntrix Biosystems, Inc. | Compositions and methods employing aminopterin |
US20080260812A1 (en) | 2004-04-26 | 2008-10-23 | Takami Matsuyama C/O Kagoshima University | Therapeutic Medicine Containing Monoclonal Antibody Against Folate Receptor Beta (Fr-Beta) |
UA86063C2 (ru) | 2004-05-03 | 2009-03-25 | Хермес Біосайенсез, Інк. | Липосомы для снабжения лекарств |
US7695908B2 (en) | 2004-06-15 | 2010-04-13 | Prometheus Laboratories Inc. | Methods for predicting methotrexate polyglutamate levels using pharmacogenetics |
WO2006029385A2 (en) | 2004-09-08 | 2006-03-16 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds. |
JPWO2006035876A1 (ja) | 2004-09-29 | 2008-05-15 | 興和株式会社 | 関節リウマチの予防及び/又は治療薬 |
US8126089B2 (en) | 2004-09-30 | 2012-02-28 | Alcatel Lucent | Method and apparatus for providing frame synchronization in a digital communication system that supports multiple modulation formats |
US20100266709A1 (en) | 2004-12-16 | 2010-10-21 | Hicks Terry Lee | Compositions and Methods for Treating Burns |
WO2006074416A1 (en) * | 2005-01-07 | 2006-07-13 | Health Research Inc. | 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
WO2007023243A2 (en) | 2005-08-24 | 2007-03-01 | Protherics Medicines Development Limited | Cleavage of antifolate compounds |
EP1962796A2 (en) | 2005-12-08 | 2008-09-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods for affecting liposome composition by ultrasound irradiation |
WO2007098089A2 (en) * | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs |
US9265746B2 (en) | 2006-05-31 | 2016-02-23 | Merck & Cie | Method for cell-specific targeting |
WO2008030818A2 (en) | 2006-09-05 | 2008-03-13 | Mebiopharm Co., Ltd. | Novel liposome compositions |
EP1900752A1 (en) | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
CA2674075C (en) * | 2006-12-29 | 2012-10-30 | Charles P. Theuer | Antifolate agent combinations in the treatment of cancer |
RU2423114C2 (ru) * | 2006-12-29 | 2011-07-10 | Тракон Фармасьютикалз, Инк. | Комбинации антифолатного агента в лечении рака |
JP2010516694A (ja) | 2007-01-19 | 2010-05-20 | チェルシー・セラピューティクス,インコーポレイテッド | 新規な伝統的葉酸拮抗剤 |
ES2387334T3 (es) | 2008-03-18 | 2012-09-20 | Btg International Limited | Derivados de ciclopenta[g]quinazolina para el tratamiento de la artritis reumatoide o la leucemia mielocítica aguda |
GB0811360D0 (en) | 2008-06-20 | 2008-07-30 | Imp Innovations Ltd | Methods |
WO2010141711A1 (en) | 2009-06-03 | 2010-12-09 | Ex-Tek, Llc | Skin treatment compositions |
TW201118098A (en) | 2009-08-13 | 2011-06-01 | Reddy S Lab Liimited Dr | Processes for preparing pemetrexed |
KR101637138B1 (ko) | 2010-02-24 | 2016-07-06 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
AU2011227686B2 (en) | 2010-03-19 | 2014-12-04 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
US9770414B2 (en) * | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
EP2394640A1 (en) | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
US20130071321A1 (en) | 2010-05-28 | 2013-03-21 | Purdue Research Foundation | Delivery of agents to inflamed tissues using folate-targeted liposomes |
EP2614084A4 (en) | 2010-09-09 | 2014-02-19 | Purdue Research Foundation | HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE |
US9261509B2 (en) | 2010-09-13 | 2016-02-16 | Thierry Dervieux | Methods for monitoring methotrexate therapy |
KR101931936B1 (ko) | 2010-11-05 | 2018-12-26 | 에이자이 아이엔씨. | 엽산 수용체 알파-발현 암에 대한 진단 및 예후 마커로서의 엽산 수용체 알파 |
WO2012078708A1 (en) | 2010-12-07 | 2012-06-14 | Chelsea Therapeutics, Inc. | Combination comprising methotrexate and an antifolate compound |
WO2012118806A2 (en) | 2011-02-28 | 2012-09-07 | The Regents Of The University Of California | Compositions and methods for detecting and treating cancer |
US9000003B2 (en) | 2011-03-10 | 2015-04-07 | National Science And Technology Development Agency | Anti-folate antimalarials with dual-binding modes and their preparation |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
PL2731591T3 (pl) | 2011-07-13 | 2021-05-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Liposomy zawierające bisfosfonian i środek amfipatyczny w wyniku ko-enkapsulacji |
TR201802838T4 (tr) | 2011-07-15 | 2018-03-21 | Eisai R&D Man Co Ltd | Anti-folat reseptör alfa antikorlar ve bunların kullanımı. |
US20130122096A1 (en) | 2011-11-14 | 2013-05-16 | Silenseed Ltd. | Compositions for drug delivery and methods of manufacturing and using same |
JPWO2014003137A1 (ja) | 2012-06-27 | 2016-06-02 | 旭化成メディカル株式会社 | 高アフィニティー抗体、及びその製造方法 |
US9440979B2 (en) | 2012-07-23 | 2016-09-13 | Fresenius Kabi Oncology Limited | Process for the preparation of pralatrexate |
WO2014046630A1 (en) | 2012-09-19 | 2014-03-27 | Keskin, Dilek | Tumor targeted liposomal drug delivery system |
US20140120157A1 (en) | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
KR20150094617A (ko) | 2012-12-07 | 2015-08-19 | 교와 핫꼬 기린 가부시키가이샤 | 항 folr1 항체 |
CN103040748B (zh) * | 2012-12-18 | 2014-07-02 | 海南圣欣医药科技有限公司 | 一种培美曲塞二钠脂质体注射剂 |
SG11201509043RA (en) | 2013-05-14 | 2015-12-30 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
CN106794164A (zh) * | 2014-08-14 | 2017-05-31 | L.E.A.F.控股集团公司 | 脂质体包封的亲和性药物 |
CN104546723B (zh) * | 2015-02-11 | 2017-07-18 | 上海交通大学医学院附属新华医院 | 一种培美曲塞脂质体及其制备方法 |
BR112018069133A2 (pt) | 2016-04-29 | 2019-01-22 | Univ Cornell | composições e métodos para penetração direcionada de partículas, distribuição, e resposta em tumores cerebrais malignos |
MX2019001756A (es) * | 2016-08-12 | 2019-05-09 | L E A F Holdings Group Llc | Antifolatos poliglutamados alfa y gamma-d y sus usos. |
WO2018031979A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
WO2018031968A1 (en) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
EP3706801A4 (en) | 2017-11-08 | 2022-04-06 | L.E.A.F Holdings Group LLC | PLATINUM COMPLEXES AND THEIR USES |
CN111936146A (zh) | 2018-02-07 | 2020-11-13 | L.E.A.F.控股集团公司 | α聚谷氨酸化四氢叶酸及其用途 |
WO2019157138A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pemetrexed and uses thereof |
JP7490240B2 (ja) | 2018-02-07 | 2024-05-27 | エル.イー.エー.エフ. ホールディングス グループ エルエルシー | ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用 |
WO2019157146A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
US20210338675A1 (en) | 2018-02-07 | 2021-11-04 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | PRALATREXATE ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
WO2019157140A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
US20210161899A1 (en) | 2018-02-07 | 2021-06-03 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
US20210169884A1 (en) | 2018-02-07 | 2021-06-10 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
WO2019157123A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
JP7491573B2 (ja) | 2018-02-07 | 2024-05-28 | エル.イー.エー.エフ. ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
WO2019160736A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
CA3090992A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
WO2019160733A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
CA3090875A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
WO2021026310A1 (en) | 2019-08-06 | 2021-02-11 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
-
2017
- 2017-08-12 MX MX2019001756A patent/MX2019001756A/es unknown
- 2017-08-12 KR KR1020197005253A patent/KR102584446B1/ko active IP Right Grant
- 2017-08-12 EP EP22167260.3A patent/EP4052729A1/en active Pending
- 2017-08-12 JP JP2019529465A patent/JP2019524885A/ja active Pending
- 2017-08-12 CA CA3033083A patent/CA3033083A1/en active Pending
- 2017-08-12 CN CN201780052159.XA patent/CN109689104A/zh active Pending
- 2017-08-12 BR BR112019002497-2A patent/BR112019002497A2/pt active Search and Examination
- 2017-08-12 CN CN201780062078.8A patent/CN109789212A/zh active Pending
- 2017-08-12 AU AU2017308158A patent/AU2017308158B2/en active Active
- 2017-08-12 EA EA201990473A patent/EA201990473A1/ru unknown
- 2017-08-12 KR KR1020237032981A patent/KR20230146097A/ko not_active Application Discontinuation
- 2017-08-12 KR KR1020197006810A patent/KR102585143B1/ko active IP Right Grant
- 2017-08-12 JP JP2019507107A patent/JP7227123B2/ja active Active
- 2017-08-12 CA CA3033077A patent/CA3033077A1/en active Granted
- 2017-08-12 KR KR1020237033296A patent/KR20230145501A/ko not_active Application Discontinuation
- 2017-08-12 BR BR112019002495-6A patent/BR112019002495A2/pt active Search and Examination
- 2017-08-12 US US16/324,823 patent/US11344628B2/en active Active
- 2017-08-12 AU AU2017308159A patent/AU2017308159B2/en active Active
- 2017-08-12 EP EP17840396.0A patent/EP3496756A4/en active Pending
- 2017-08-12 MX MX2019001755A patent/MX2019001755A/es unknown
- 2017-08-12 EP EP17840397.8A patent/EP3496757A4/en active Pending
- 2017-08-12 CA CA3177187A patent/CA3177187A1/en active Pending
-
2019
- 2019-02-11 MX MX2022009187A patent/MX2022009187A/es unknown
- 2019-02-11 MX MX2023007496A patent/MX2023007496A/es unknown
- 2019-02-11 MX MX2023007726A patent/MX2023007726A/es unknown
-
2021
- 2021-12-07 US US17/544,196 patent/US20220088220A1/en active Pending
- 2021-12-07 US US17/544,182 patent/US20220088218A1/en active Pending
- 2021-12-07 US US17/544,191 patent/US20220088219A1/en active Pending
-
2022
- 2022-06-22 JP JP2022100445A patent/JP2022126790A/ja active Pending
- 2022-07-28 US US17/875,724 patent/US11701432B2/en active Active
-
2023
- 2023-02-09 JP JP2023018363A patent/JP2023058619A/ja active Pending
- 2023-05-24 US US18/201,275 patent/US20230381338A1/en active Pending
- 2023-11-07 AU AU2023263441A patent/AU2023263441A1/en active Pending
- 2023-11-07 AU AU2023263442A patent/AU2023263442A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023007496A (es) | Antifolatos poliglutamados y sus usos. | |
EA201990324A1 (ru) | Альфа- и гамма-d-полиглутамированные антифолаты и их применение | |
PH12018500950A1 (en) | Subcutaneous formulations of anti-cd38 antibodies and their uses | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
MX2019003735A (es) | Formulaciones diluibles de cannabinoides y procesos para su preparacion. | |
MX2019003489A (es) | Moleculas del receptor de envolvimiento quimerico. | |
PH12016502115B1 (en) | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS | |
ZA201908214B (en) | Anti-bcma heavy chain-only antibodies | |
MY191581A (en) | Anti-pd-1 antibodies | |
MX2019013670A (es) | Formulaciones de anticuerpos y proteinas. | |
EP4292600A3 (en) | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells | |
MX2019015563A (es) | Anticuerpos anti-bcma unicamente de cadena pesada. | |
EP3463399A4 (en) | METHODS OF TREATING AUTOIMMUNE DISEASE USING ALLOGENIC T CELLS | |
WO2017214170A3 (en) | Baff-r antibodies and uses thereof | |
MX2018000395A (es) | Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso. | |
PH12016501689B1 (en) | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof | |
MX2019011613A (es) | Formulaciones de acido 1-amino-1-ciclopropanocarboxilico. | |
MX2017006513A (es) | Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor. | |
MX2022010827A (es) | Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados. | |
MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
NZ721832A (en) | Solid forms of tenofovir | |
CR20200202A (es) | Metodos de uso y composiciones que contienen dulaglutida | |
PH12017501525A1 (en) | Gene therapy to improve vision |